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Background: People in green professions are exposed to a variety of risk factors, which could possibly enhance the
development of depression. Amongst possible prevention approaches, internet- and mobile-based interventions
(IMIs) have been shown to be effective and scalable. However, little is known about the effectiveness in green
professions. The aim of the present study is to examine the (cost-)effectiveness of a tailored IMI program for
reducing depressive symptoms and preventing the onset of clinical depression compared to enhanced treatment
as usual (TAU+).
Methods: A pragmatic randomized controlled trial (RCT) will be conducted to evaluate a tailored and
therapeutically guided preventive IMI program in comparison to TAU+ with follow-ups at post-treatment (9 weeks),
6-, 12-, 24-, and 36-months. Entrepreneurs in green professions, collaborating spouses, family members and
pensioners (N = 360) with sufficient insurance status and at least subthreshold depression (PHQ-9 ≥ 5) are eligible
for inclusion. Primary outcome is depressive symptom severity (QIDS-SR16). Secondary outcomes include incidence
of depression (QIDS-SR16), quality of life (AQoL-8D) and negative treatment effects (INEP). A health-economic
evaluation will be conducted from a societal perspective. The IMI program is provided by psychologists of an
external service company and consists of six guided IMIs (6–8 modules, duration: 6–8 weeks) targeting different
symptoms (depressive mood, depressive mood with comorbid diabetes, perceived stress, insomnia, panic and
agoraphobic symptoms or harmful alcohol use). Intervention choice depends on a screening of participants’
symptoms and individual preferences. The intervention phase is followed by a 12-months consolidating phase with
monthly contact to the e-coach.
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Discussion: This is the first pragmatic RCT investigating long-term effectiveness of a tailored guided IMI program
for depression prevention in green professions. The present trial builds on a large-scale strategy for depression
prevention in green professions. The intended implementation of the IMI program with a nationwide rollout has
the potential to reduce overall depression burden and associated health care costs in case of given effectiveness.
Trial registration: German Clinical Trial Registration: DRKS00014000. Registered on 09 April 2018.
Keywords: Prevention, Depression, Internet- and mobile-based interventions, Green professions, RCT,Background
Major depressive disorder (MDD) is a highly prevalent
disorder in the general population: a 12-month prevalence
of MDD amounts to 6.7% [1], while lifetime prevalence is
estimated at 10.6 to 19.8% [2]. MDD is associated with
substantial functional impairment [3, 4] and has been
identified as a leading cause of global disease burden [5].
In addition to the high individual burden, the socioeco-
nomic costs associated with MDD and its comorbid
physical and psychiatric disorders due to medical use, ab-
senteeism, loss of productivity at work and suicide, are
enormous [6].
An estimation of prevalence rates in the specific
target group of green professions in Germany has yet
to be conducted. However, people in green profes-
sions are exposed to a variety of risk factors, which
might increase vulnerability for developing MDD. Risk
factors include financial pressure, high administrative
workload, long working hours, high stress levels, part-
time jobs off the farm, health problems and preceding
work accidents [7, 8], as well as continuous exposure
to pesticides [8–10]. In addition, an increased risk of
suicide in the agricultural sector was reported across
different countries e.g. in England and Wales [11, 12],
the USA [13–15], Australia [16, 17], and Brazil [9].
Based on given risk factors and risk of suicide, pre-
ventive measures are highly indicated.
Psychological interventions for subthreshold depression
as indicated prevention have been shown to significantly
reduce depressive symptom severity [18]. Additionally,
such interventions might even prevent the onset of major
depression [18, 19]. Thus, preventive interventions can
have a substantial role in reducing overall depression bur-
den in green professions.
Although face-to-face psychotherapy represents an ef-
fective treatment option, impact of such on-site offers is
restricted. MDD is still an underdiagnosed and under-
treated condition with only approximately 50% of per-
sons with 12-month MDD receiving some kind of
treatment, and only approximately 20% of affected per-
sons receiving an appropriate treatment concordant with
treatment guidelines [4]. In Germany, availability of on-
site psychotherapy is restricted by long waiting timesand is furthermore lower in rural areas than in urban
areas [20].
Internet- and mobile-based interventions (IMIs) have
already shown to be effective in reducing subthreshold
depression [21–25] and thus, pose a suitable alternative
treatment option to on-site psychotherapy. While short-
term effectiveness of IMIs regarding depression severity
at post-treatment is well established, studies on long-
term effectiveness are scarce and yield inconsistent evi-
dence [26].
IMIs constitute a promising approach for providing an
effective and easily accessible prevention offer in routine
health care [27, 28]. As IMIs can be used independently
of time and place, they are easily accessible even in rural
areas and have the potential to increase acceptance and
utilization of psychological interventions [29]. Currently,
little is known about acceptance, effectiveness or
utilization of IMIs in the specific target group of green
professions.
To improve the delivery situation in rural areas, and
specifically for the target group of green professions, this
study will be conducted in the framework of a national
depression prevention program for people in green pro-
fessions, implemented by the Social Insurance for Agri-
culture, Forestry and Horticulture (SVLFG, http://www.
svlfg.de/). The SVLFG currently establishes a compre-
hensive prevention model project (“With us in balance”)
for their insurees with the offered services of guided
IMIs, personalized tele-based coaching as well as on-site
prevention group workshops, provided by different ser-
vice providers in the health care sector. Parallel to a na-
tionwide rollout, the single internet- or telephone-based
prevention offers will be evaluated in randomized con-
trolled clinical trials (RCTs) in order to establish evi-
dence on the clinical and cost-effectiveness. Eligible for
this trial are policyholders of the SVLFG who are entre-
preneurs, family members, spouses or have retired in
one of the three sectors of agriculture, forestry or horti-
culture (referred to as “green professions”).
In the present study, IMIs for the prevention of de-
pression provided by the health care company GET.ON
will be evaluated regarding effectiveness and cost-
effectiveness. GET.ON institute offers scientifically
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pressed mood in general or in the context of diabetes
mellitus, insomnia, stress, panic and agoraphobic symp-
toms and harmful alcohol use). Even though these IMIs
differ regarding their focus on mental health problems,
they will be evaluated as part of a depression prevention
program. The underlying idea follows the rational of a
transdiagnostic approach: Transdiagnostic research has
already yielded promising evidence that treatment proto-
cols based on transdiagnostic maintaining factors and
treatment concepts can lead to symptom reduction com-
parable to disorder-specific treatments [30, 31]. This
already indicates that psychological interventions do not
necessarily need to be disorder-specific and labeled ac-
cordingly to achieve symptom alleviation.
Especially in prevention context, it is desirable to reach
and provide preventive interventions for a large popula-
tion sample. Low adherence and high dropout rates [32,
33] restrict impact of IMIs. Treatment credibility and
treatment motivation have been shown to predict treat-
ment adherence [34, 35]. Thus, measures to increase mo-
tivation or treatment credibility are highly desirable, as
they improve participation in preventive interventions and
reduce dropout rates of participants [36–39]. The (cost)ef-
fectiveness of this tailored and guided prevention ap-
proach is especially interesting, as it leaves room for
greater emphasis on personal interest and treatment
motivation in the selection procedure of an appropri-
ate intervention. Further, stigma against depression
can still be a common issue in rural areas [40, 41].
This patient-centered and complaint-based approach
also has the potential to improve the uptake of IMIs
especially for depression prevention, by avoiding the
exclusive label of “depression” and potentially associ-
ated stigma.
Objective and research question
The aim of the present study is to investigate whether a
tailored IMI program targeting a variety of specific com-
plaints associated with clinical depression is useful in re-
ducing depressive symptoms and preventing onset of
clinical depression as compared to enhanced treatment
as usual (TAU+) within a 36-month follow-up period.
We propose, that depressive symptomology will be re-
duced to a greater extent in the intervention group (e.g.
IMI program) than in the control condition (e.g. TAU+)
post-treatment (T1). The following research questions
will be investigated in this pragmatic randomized con-
trolled trial over a follow-up period of 36-months:
– Is the IMI program effective in reducing depressive
symptom severity compared to TAU+?
– Is the IMI program effective in preventing the onset
of clinical depression as compared to TAU+?– Is the IMI program effective in reducing various
mental health outcomes (e.g. stress, anxiety,
insomnia) compared to TAU+?
– Is there a differential or rather an undifferentiated,
general effect of specific IMIs on different mental
health outcomes?
– Is the IMI program superior in terms of cost-
effectiveness and QALY health gains compared to
TAU+?
– Which variables moderate and mediate the effects of
the IMI program?
– What is the level of intervention satisfaction,
adherence and acceptance to the IMI program?
– Are there negative effects of the IMI program?
Methods
Study design
A two-armed pragmatic randomized controlled trial
(RCT) will be conducted comparing the clinical and
cost-effectiveness of a tailored, guided IMI program to a
control group (CG) receiving enhanced treatment-as-
usual (TAU+). Primary and secondary outcomes will be
assessed over a period of 36 months. Assessments will
take place at baseline (T0), post-treatment (nine weeks,
T1), as well as at 6-month (T2), 12-month (T3), 24-
month (T4) and 36-month (T5) follow-up.
This clinical trial has been approved by the ethics com-
mittee of University of Ulm (No. 454/17) and will be re-
ported in accordance with the Consolidated Standards of
Reporting Trials (CONSORT) Statement 2010 and the ex-
tension for reporting pragmatic trials [42–44] as well as the
guidelines for executing and reporting internet intervention
research [45]. This trial protocol was created according to
SPIRIT guidelines [46, 47]. This study is registered in the
German clinical trial register under DRKS00014000.
Participants & procedure
Inclusion and exclusion criteria
We will include a) agriculturists, foresters and horticultur-
ists with sufficient insurance status of a social insurance
company (SVLFG) in Germany. The study is accessible for
entrepreneurs, collaborating spouses and family members
as well as pensioners who do no longer contribute to the
production process with sufficient insurance status. Partici-
pants are required to b) be age 18 or above, c) show an in-
dication for at least subthreshold depression (PHQ-9 ≥ 5),
d) have internet access, and e) be willing to give informed
consent. Participants will be excluded a) if they are cur-
rently receiving psychotherapy (self-report), b) if they are
not able to distance themselves from suicidal ideation (not
able to sign a non-suicide contract), and c) if they have co-
morbid chronic pain symptomology (Chronic Pain Grade
Questionnaire (CPG) ≥Grade II + chronic pain longer than
six months) and prefer to participate in the parallel clinical
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with chronic pain (Terhorst Y, Braun L, Titzler I, Buntrock
C, Freund J, Thielecke J, et al.: Effectiveness and cost-
effectiveness of an acceptance and commitment therapy to
improve chronic pain-related disability in green professions
(PACT-A): study protocol of a 36-month follow up prag-
matic randomized controlled trial, in preparation).
Recruitment
This clinical trial is embedded in a large-scale mental
health initiative of the SVLFG with the aim to improve
the prevention of mental health problems in agricultur-
ists, foresters and horticulturists. Participants are re-
cruited via several articles in the members-journal
(quarterly circulation 1.3 million), postal mailings as well
as information on associated websites. Since interested
persons are provided with various ways of contact (via
postal return element, fax, e-mail, telephone) and an
alternatively direct access to the screening assessment
(via QR-Code and URL), a low-threshold access into theFig. 1 Overview of study procedurestudy is provided. Recruitment started in January 2018
and was concluded in April 2019 (Fig. 1).
Assessment of eligibility and randomization
People are screened for eligibility via an online screening
questionnaire. Screening includes online questionnaires to
assess the presence and the severity of depressive (PHQ-
9 ≥ 5) and chronic pain symptomology (CPG ≥Grade II +
chronic pain longer than six months), as well as possible
suicidal ideation. Online questionnaires include self-report
of age, insurance status, and current psychotherapy. If the
eligibility criteria are fulfilled, applicants will receive an
online information letter including detailed information
about study procedure and informed consent. They will
be informed that they can withdraw from the intervention
and/or study at any time without any negative conse-
quences. After giving informed consent, participants will
enter the study and complete baseline assessment (T0).
Subsequently, participants will be randomly allocated to
intervention or control condition and will be informed
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take place at an individual level. Randomization will be
conducted by a person who is blind regarding all pro-
cesses within the intervention. Whereas blinding of partic-
ipants is not possible, data collectors are blinded regarding
group membership. Group membership is only known by
the persons administering allocated treatments to partici-
pants. The automated web-based programme sealed enve-
lope (www.sealedenvelope.com) is used to perform
permuted block randomization with randomly arranged
block sizes (8, 10, 12) and an allocation ratio of 1:1.
Written informed consent for participation in online-
assessments will also be obtained from e-coaches. No eli-
gibility criteria are applied by the study team for selection
and assignment of e-coaches. E-coaches are employed,
assigned, guided and supervised by the GET.ON institute
regarding their task of counselling the study participants.
Intervention
Intervention condition
Participants in the intervention group (IG) will be transferred
to the service provider GET.ON to get access to a tailored
and guided IMI program with the option of conducting one
of six available IMIs. The IMI program consists of a 3-step
intervention entailing (1) psycho-diagnostic assessment, (2)
participatory selection of a suitable (guided) IMI and (3) ac-
cess to IMI. The IMI program will be carried out by the ex-
ternal service company GET.ON without involvement from
the study team. Thus, the GET.ON institute is responsible
for providing an adequate care of the participants against the
background of the psycho-diagnostic assessment and the in-
formation they receive in the course of patient contact. This
includes for example the handling of adverse events in the
course of e-coaching. The study team evaluates in this set-
ting the standard procedure of the GET.ON institute for the
allocation of the different trainings and the treatment of par-
ticipants in the course of the IMI program.
(1) The psycho-diagnostic assessment is based on a
selection of self-report questionnaires measured as
part of baseline assessment (T0). Relevant baseline
assessment values are transmitted electronically to
GET.ON for each participant to allow for psycho-
diagnostic assessment based on allocation rules ap-
plied in supply routine of GET.ON. Each partici-
pant is assigned to a personal e-coach after signing
in to the intervention platform. E-coaches are
trained psychologists, who are in training for a fur-
ther qualification in psychotherapy and supervised
by an experienced psychological therapist.
(2) Participants are contacted via telephone or private
message function on the intervention platform by
their personal e-coach for participatory selection of
a suitable (guided) IMI.The IMI program entails six different IMIs with the
aim to reduce subthreshold depression by focusing on
depressed mood in general (GET.ON Mood Enhancer)
or in the context of a comorbid diabetes mellitus
(GET.ON Mood Enhancer Diabetes), by improving
sleep quality (GET.ON Recovery), or by reducing
subjective stress load (GET.ON Stress), panic symptoms
(GET.ON Panic), or harmful alcohol use (GET.ON Be
smart - Drink less). These interventions have already
been shown to effectively reduce depressive symptom
severity as primary [23, 25, 48, 49] or secondary
outcome [24, 50–55], (Ebenfeld L, Lehr D, Ebert D,
Kleine Stegemann S, Funk B, Riper H, et al.: Treating
panic on the go: results of a randomized controlled trial
evaluating a hybrid online-training for panic and
agoraphobia symptoms, in preparation) to prevent the
incidence of MDD [24] in other target groups.
Moreover, health economic outcome evaluations
alongside randomized trials indicate a promising cost
benefit [56–59].
The type of the IMI is chosen depending on psycho-
diagnostic assessment as well as individual participant
needs, personal preference and problem areas, which
are reported in the course of the conversation.
(3) Directly afterwards the participants will receive
access to the selected IMI. The IMIs each consist of
6–8 lessons with a duration of 30–60 min.
Participants are advised to do one lesson per week.
Thus, completion of the intervention is expected to
take 6–8 weeks. Depending on the individual pace
of the participant, the completion of the
intervention can differ. After each lesson,
participants get an individualized feedback by their
personal e-coach. Guidance is employed to improve
adherence of participants and decrease dropout
[60]. Depending on the participant’s preference,
feedback is given either by telephone or through
the internal messaging function of the system in
which the online-training is implemented. After-
wards the next lesson is unlocked for the use. In ex-
ceptional cases, it is possible to switch the training
directly if the assigned tailored intervention is per-
ceived to be unsuitable by the participant.
The IMIs are based on principles of cognitive behav-
ioural therapy (GET.ON Mood Enhancer, GET.ON Mood
Enhancer Diabetes, GET.ON Recovery, GET.ON Panic,
GET.ON Be smart - drink less) and on the transactional
model of stress and coping [61] (GET.ON Stress).
(a) GET.ON Mood Enhancer aims to reduce depressed
mood by promoting the uptake of positive activities
and the learning of problem-solving strategies [62].
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of GET.ON Mood Enhancer and aims to reduce
depressed mood in the context of diabetes mellitus [63].
(c) GET.ON Recovery is directed towards persons with
clinical insomnia complaints and aims to prevent
depression by improving participants’ sleep quality,
especially through modifying coping behaviour
regarding rumination and worrying. This is
achieved by assignments such as keeping a diary
about ruminating thoughts [64].
(d) GET.ON Stress aims to reduce depressive
symptomology by addressing chronic stress and
reducing stress-related complaints. The training in-
structs to apply problem- and emotion-oriented
stress management strategies based on the distinc-
tion between solvable and unsolvable problems [65].
(e) GET.ON Panic aims to reduce depressive symptoms by
addressing panic symptoms and agoraphobia.
Participants are instructed to perform in-vitro and in-
vivo exposition. Further, the training comprises infor-
mation and exercises for coping with negative auto-
matic thoughts and for establishing positive thought
processes [66]. If this training is assigned, participants
are requested by their consecutive e-coach to clarify
their physical symptoms with their GP in advance to
rule out the presence of physical illnesses (e.g. cardio-
vascular diseases). The consultation of the GP is the re-
sponsibility of the participant and will not be controlled.
(f) GET.ON Be smart - drink less was developed to
prevent depression by reducing harmful alcohol use
in participants, who do not yet meet clinical criteria
for alcohol dependence. This training aims to
identify emotions and situations associated with
alcohol consumption by keeping an alcohol-diary.
Further, alternative exercises for actions for coping
with negative emotions and problems are included
[67]. This training will not be assigned to participants
with a hazardous drinking level score of > 20 on
AUDIT. In case of AUDIT > 20, participants will re-
ceive access to a different training of the portfolio
which is most fitting to the complaints and be made
aware of their hazardous drinking level by their con-
secutive e-coach. If interested, the e-coach will provide
them with a list of addresses, which they can turn to.
The IMIs are accessible on an online-based interven-
tion platform via either computer (e.g. desktop PC, lap-
top) or mobile device (e.g. tablet, smartphone). The IMIs
contain psycho-educative text material, exercises, and
testimonials of exemplary personas, who accompany the
participants throughout the intervention. Additionally,
interactive elements in form of auditory material and
videos clips are included. Audio clips for example are
used to convey relaxation techniques, while video clipsoften serve to give a comprehensible overview about the-
oretical concepts by experts. Since a focal point is the
transfer of content and strategies learned into every-day
life, many application examples, instructions and exercises,
as well as homework assignments for practising between
lessons are included. The content of the online-trainings
has been specifically adapted to the target population by in-
clusion of fitting picture and video material, as well as ex-
emplary testimonials and fictional personas living and
working in the agricultural setting. These personas describe
the struggle with everyday problems and challenges in
green professions, e.g. generational conflicts or handing
over of the company to the younger generation.
Subsequent to the completion of the IMI, participants are
followed up for 12months by their individual e-coach to con-
solidate the treatment effect. During this phase, participants
are contacted once a month through telephone or the in-
ternal messaging system by their personal e-coach to review
their current state, report problems, and give account regard-
ing the transfer of strategies learned into the daily routine.
Control condition
Both participants of the IG and the CG will have unrestricted
access to treatment-as-usual (TAU). Participants of the CG
will receive an online information letter with psycho-
educative information about stress, depression and chronic
pain. Additionally, a link to an online freely available audio
CD with information about stress reduction is provided, as
well as a link to a database with different health services and
information about further treatment options in standard care
(enhanced treatment as usual (TAU+) for the CG).
TAU will not follow a standardized protocol, however,
health care consumption will be measured with the TiC-
P [68] (see measures below). Hence, an accurate descrip-
tion of TAU can be provided.
Sample size/power calculation
In this trial, the effectiveness of the IMI program in re-
ducing depression severity is compared to TAU+. The
estimation of sample size was based on a meta-analysis
by Zhou and colleagues (2016) [26], who reported an ef-
fect size of SMD = 0.46 [95%-CI: 0.22–0.70] for IMIs in
the reduction of subclinical depressive symptoms. In this
meta-analysis mostly waitlist control groups where in-
cluded. Since comparison of IG with TAU+ presumably
yields a smaller effect size than comparison with waitlist
control group [69], we assumed a conservative effect size
of d = 0.35 for the present trial. An effect size of g = 0.35
[95%-CI: 0.23–0.47] was also reported in a meta-analysis
as the effect of psychotherapy on reduction of depressive
symptom severity in subthreshold depression with more
than a half of the included studies applying care as usual
in the CG [18]. Based on prior findings [23–25, 48–55],
(Ebenfeld L, Lehr D, Ebert D, Kleine Stegemann S, Funk
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randomized controlled trial evaluating a hybrid online-train-
ing for panic and agoraphobia symptoms, in preparation)
and the above stated hypothesis, a one-sided t-test (α = 0.05;
1-β= 0.90) with a ratio of 1:1 (IG:CG) is used for power cal-
culation. Power calculation was conducted with G*Power
(Version 3.1.9.2) and resulted in an overall sample size of
282 participants. According to a meta-analysis approximately
28% percent of dropout occurred across a sample of studies
evaluating efficacy and effectiveness of online-based interven-
tions for depression with therapeutic support [69]. To com-
pensate for an expected dropout of 28%, the present study
aims at an overall sample size of 360 participants.
Assessments
All assessments will be conducted online. For an over-
view of instruments at screening, baseline (T0), post-
treatment (T1), and follow-up assessments (T2-T5), see
Table 1. Participants will receive 10€ for completion of
each follow-up assessment, starting with T1.
Screening
The preliminary screening assesses sociodemographic vari-
ables (age, gender, employment relationship, insurance sta-
tus) and information about various recruitment channels.
The German Version of the Patient Health Questionnaire
(PHQ-9) [70] is administered as a depression screening in-
ventory to detect subthreshold depression (PHQ-9 ≥ 5).
The PHQ-9 consists of 9 items on a 4-point-scale with a
rating scale ranging from 0 to 3 (0 = “not at all”, 1 = “several
days”, 2 = “more than half the days”, 3 = “nearly every
day”). Each item covers one symptom criterion domain of
MDD. Additionally, an item is included to register severity
of daily life limitations associated with depressive symp-
toms. The computerized version of the PHQ-9 (α = 0.88)
shows an equally high internal consistency as the paper-
pencil version (α = 0.89) [71]. Item 9 of BDI-II [72] will be
applied to screen for suicidal ideation.
The Chronic Pain Grade Scale (CPG) [73] is applied to
screen for chronic pain syndrome in combination with an
additional item to measure chronicity of pain. The CPG
grades pain severity by using the two dimensions “pain inten-
sity” and “disability”. Severity of pain is categorized into the
four hierarchical classes “Grade I” to “Grade IV”. The Ger-
man Version of the CPG [74] showed overall a good internal
consistency (α= .82). The German Version was adapted for
this study to evaluate overall pain over the last 6months.
Outcome measurements
Primary outcome
Depressive symptom severity at post-treatment (T1)
The primary outcome is depressive symptom severity at
post-treatment (T1), assessed with the German Version of
the Quick Inventory Depressive Symptomology (QIDS-SR16) [75]. The 16-item self-report inventory covers all
nine DSM-5 symptom criterion domains of MDD. The
QIDS-SR16 is characterized by high internal consistency
of α= .86 [75]. The items are rated on a 4-point-scale ran-
ging between 0 and 3. The total score ranges between 0 and
27, with a higher score indicating higher depressive symptom
severity. Whereas a score between 0 and 5 indicates normal
health status, scores between 6 and 10 indicate mild depres-
sive symptomology, between 11 and 15 moderate, between
16 and 20 severe and scores greater than 20 indicate very se-
vere depressive symptomology. Since the QIDS-SR16 is sen-
sitive to symptom change and provides very similar results
compared to longer clinical ratings like HAM-D17, HAM-
D21, and HAM-D24 [75], this inventory will be administered
to monitor changes in depressive symptom severity.
Secondary outcomes
Depressive symptom severity at follow-up (T2 – T5)
Depressive symptom severity will be measured over a period
of 36months at 6-month (T2), 12-month (T3), 24-month
(T4) and 36-month (T5) follow-up with QIDS-SR16.
Depression response
Clinical significance of depression response will be deter-
mined with QIDS-SR16 scores according to Jacobson and
Truax [76].
Onset of clinical depression and bipolar disorder
Additionally, QIDS-SR16 will be used to classify participants
regarding presence of clinical depression at all measurement
points (T0-T5). A comparison of QIDS-SR16 scores to
current and lifetime diagnosis based on Structured Clinical
Interview for DSM-IV-TR Axis I Disorders (SCID) as meas-
ure criterion showed that QIDS-SR16 is a reliable screening
instrument for diagnosis of clinical depression [77]. Cut-off
scores of 13 and 14 yielded best results for sensitivity (76.5%)
and specificity (81.8%) leading to correct classification of over
80% of participants [77]. For this study, a score ≥ 13 is
defined as cut-off to identify possible cases of clinical depres-
sion for all measurement points within the 36-month follow-
up period.
Further, Items adapted from the Composite International
Diagnosis Interview version 3.0 (CIDI 3.0) and Screening
Scales (CIDI-SC) [78], and the Epi-Q Screening Survey [79]
as applied in the WHO World Mental Health Surveys
International College Student Project [80] are used to assess
presence of major depressive episode (MDE) and bipolar
disorder (BPD) at all measurement points. Items recording
onset and frequency of MDE and BPD episodes are included.
Perceived Stress
The 10-item version of the perceived stress scale (PSS-
10) [81, 82] will be used to measure the perception of
stress in participants. The scale particularly assesses how
Table 1 Overview of the assessments
Instruments Aim Time of measurement
Screening T0 T1 T2 T3 T4 T5
Screening Instruments
PHQ-9 Patient Health Questionnaire ✔
CPG Chronic Pain Grade Questionnaire ✔
Chronicity of Pain Pain longer for 6 months (yes/no) ✔
Primary Outcome
QIDS-SR16 Quick Inventory for
Depressive Symptomatology
✔ ✔a ✔ ✔ ✔ ✔
Secondary Outcomes
Adapted items from CIDI 3.0,
CIDI-SC, and Epi-Q Screening Survey
Prevalence of major depression
and bipolar disorder
✔ ✔ ✔ ✔ ✔ ✔
PSS-10 Perceived Stress Scale ✔ ✔ ✔ ✔ ✔ ✔
ISI Insomnia Severity Index ✔ ✔ ✔ ✔ ✔ ✔
GAD-7 Generalized Anxiety Disorder ✔ ✔ ✔ ✔ ✔ ✔
PAS Panic and Agoraphobia Scale ✔ ✔ ✔ ✔ ✔ ✔
MPI Multidimensional Pain Inventory ✔ ✔ ✔ ✔ ✔ ✔
NRS Pain Intensity (0–10) ✔ ✔ ✔ ✔ ✔ ✔
AUDIT-10 Alcohol use disorder identification test ✔ ✔ ✔ ✔ ✔ ✔
MBI-GS Maslach-Burnout-Inventory
(subscale emotional exhaustion)
✔ ✔ ✔
AQoL-8D Quality of life ✔ ✔ ✔ ✔ ✔ ✔
SPE Subjective prognosis of employment ✔ ✔ ✔ ✔ ✔ ✔
Cost measurement
TiC-P Utilisation of health services,
work-related productivity
✔ ✔ ✔ ✔ ✔ ✔
Intervention-related Outcomes
WAI-SRb, WAI-SRTc Therapeutic relationship ✔ ✔
TAI-OTb Technological alliance ✔ ✔
CSQ-I Patient satisfaction ✔
INEPb Inventory of negative
effects in psychotherapy
✔ ✔ ✔
Negative effectsb Negative effects in psychotherapy ✔ ✔ ✔
Other assessments
Other questions Socio-demographics ✔
Predictors for development
of major depression
✔
Diabetes Diabetes diagnosis (yes/no) ✔
BDI-II Suicidality-Item ✔ ✔ ✔ ✔ ✔ ✔ ✔
aPrimary outcome is the standardized mean difference between intervention and control group at T1. QIDS-SR16 will also be assessed at T0 and T2-T5
bRecorded in intervention group only
cRecorded in e-coaches only
T0 Baseline, T1 9 weeks, T2 6 months, T3 12 months, T4 24 months, T5 36 months
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dents find their lives” [83]. For the PSS-10 satisfactory
internal consistencies from α = .78 to α = .91 were re-
ported [83]. In a representative German community
sample, a Cronbach’s alpha of .84 was reported forPSS-10 [84]. The PSS-10 was modified to address per-
ception of stress load in the last week instead of the last
month, because post-assessment (T1) is 9 weeks after
randomization and duration of online-training lies be-
tween 6 to 8 weeks.
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Insomnia Severity will be measured using the Insomnia
Severity Index (ISI) [85]. The ISI is a brief self-report
scale composed of seven items to identify clinical insom-
nia. The questionnaire has been validated in clinical and
community samples and is characterized by high internal
consistency (α = 0.90 to 0.92) and adequate discrimina-
tive validity of the individual items [86, 87]. The German
version of the ISI was examined in three cross-sectional
studies in different target groups [88]. Cronbach’s Alpha
was shown to be satisfactory in all three samples (α = .76
in adolescents, α = .77 in young adults, α = .81 in adult
workers) [88].Generalized Anxiety Disorder
The GAD-7 [89] will be used as a short self-report meas-
ure to assess likelihood of Generalized Anxiety Disorder.
In the United States a high internal consistency of α = .92
was reported for the seven items of GAD-7. In a German
sample, an internal consistency of α = .89 was found [90].
Overall, the GAD-7 is a valid and reliable instrument to
screen for Generalized Anxiety Disorder [89, 90].Panic and Agoraphobia
The severity of panic and agoraphobic symptoms will be
assessed with the self-report version of the panic and
agoraphobia scale (PAS) [91, 92]. The 13-item scale com-
prises five subscales, assessing panic attacks, agoraphobic
avoidance, anticipatory anxiety, daily life limitations and
health concerns. Additionally, the PAS contains an extra
item for assessing unexpectedness versus expectedness of
panic attacks, which is not included in the calculation of
the total score [91]. The PAS was found to have a high in-
ternal consistency of α = .88 [91].Pain intensity and pain associated disability
Assessment instruments for measurement of pain inten-
sity and pain associated disability were selected under
consideration of the recommendations of the Initiative
on Methods, Measurement and Pain Assessment in
Clinical Trials (IMMPACT) [93, 94].
The Multidimensional Pain Interference Scale (MPI)
[95, 96] is administered to measure the degree of pain-
associated disability regarding all-day activities. The Ger-
man version of the MPI consists of 10 items rated on a 7-
point scale. The MPI is characterized by excellent internal
consistency (Cronbach’s alpha = .94) and good retest reli-
ability (r = .78). Additionally, pain intensity will be recorded
using an 11-point numerical rating scale from 0 (“no pain”)
to 10 (“pain as bad as you can imagine”). This scale will be
applied to rate the worst, least, average and current pain
participants experienced during the last seven days.Alcohol consumption
The Alcohol Use Disorder Identification Test (AUDIT)
[97] will be applied to screen for harmful alcohol use. The
AUDIT has been validated in six different countries and
therefore is cross-nationally applicable [98, 99]. The 10-
item self-report questionnaire measures a unidimensional
construct with adequate internal consistency ranging be-
tween α = .8 and α = .83 [100, 101]. Validation of the
AUDIT in a German general practice sample showed high
retest reliability (ICC = .95) and adequate validity [102]. In
the present study, the German Münster Version of the
AUDIT following S3 guideline was applied (http://audi-
tscreen.org/cmsb/uploads/audit-german-m-nster.pdf).
Emotional Exhaustion
Emotional exhaustion as the basic dimension of the
burnout construct will be measured with a subscale of
the Maslach Burnout Inventory (MBI-GS) [103]. In the
present study, a German translation by Cillien and col-
leagues (2006) [104] was used. The 5-item subscale was
applied to assess emotional exhaustion.
Quality of Life
Health-related quality of life will be assessed with the self-
report questionnaireassessment of Quality of Life (AQoL-
8D). This questionnaire consists of 35 items, covering the
three physical dimensions “independent living”, “pain”, and
“senses”, as well as the five psycho-social dimensions “men-
tal health”, “happiness”, “coping”, “relationships”, and “self-
worth” [105]. The AQoL-8D is characterised by a high
Cronbach’s Alpha of 0.96 and good psychometric proper-
ties [105] and will be applied for cost-utility analyses.
Work capacity
Work capacity will be measured with the German version
of the Subjective Prognostic Employment Scale (SPE)
[106]. The SPE is a validated short self-report scale com-
posed of 3 items with high internal consistency (Guttman
scaling: rep = .99) for assessment of subjective endanger-
ment and prognosis of work capacity [106].
Cost measures
The provider (GET.ON institute) will provide information
about the intervention costs, including costs pertaining ini-
tial phone calls by psychologists, documentation and coach-
ing (e.g. individual written feedback) provided by qualified
psychologists, technical support, server for hosting the in-
terventions and overhead. Cost evaluation will be based on
the German version of the Dutch cost questionnaire “Trim-
bos Institute and Institute of Medical Technology Ques-
tionnaire for Costs Associated with Psychiatric Illness”
(TiC-P) [68]. In this self-report questionnaire, the usage of
health care services (e.g. general practice services, intake of
medications, sessions with psychotherapists or psychiatrists)
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entism) is assessed. We will follow the human capital ap-
proach to value productivity losses [107]. The questionnaire
was specifically adapted to the population of agriculturists,
forester and horticulturists. A list of unit cost prices will be
used to compute the total health care costs on a per-
participant basis [108].
Intervention-related outcomes
Experience of Working and Technological Alliances
The short version of the Working Alliance Inventory
(WAI-SR) [109] will be applied to measure the thera-
peutic alliance between client and e-coach. The 12-item
self-report questionnaire covers the three subscales a)
agreement on tasks, b) agreement on goals and c) devel-
opment of an affective bond. For the German Version,
internal consistencies between α = .81 and α = .91 were
reported for the subscales and internal consistencies be-
tween α = .90 and α = .93 for the total score [109, 110].
Participants in IG will complete the WAI-SR at T1 and
T3. Additionally, e-coaches will be requested to
complete the 10-item therapist version (WAI-SRT, de-
veloped by Adam O. Horvath, http://wai.profhorvath.
com/) at T1 and T3. This will allow us to compare how
the therapeutic relationship is experienced by client and
by e-coach, to gain a differentiated and comprehensive
picture of the experienced working alliance. The WAI-
SR and the WAI-SRT were adapted in wording for the
current study investigating therapeutic alliance in guided
IMIs. The items were changed to refer to e-coaches in-
stead of therapists and to online-trainings instead of
therapy. Additionally, the Technological Alliance Inven-
tory - Online Therapy (TAI-OT) will be administered to
assess the technological alliance between client and the
online-intervention. The TAI-OT is a new self-report
questionnaire developed by Labpsitec (http://www.labp-
sitec.uji.es/esp/index.php) consisting of 12 items and
measures the degree to which the online-program is per-
ceived as helpful in achieving therapeutic goals.
Intervention satisfaction
Intervention satisfaction will be assessed using a German
Version of the Client Satisfaction Questionnaire (CSQ-8
[111]; German Version: ZUF-8 [112]), specifically adapted
for assessing patient satisfaction with IMIs (CSQ-I) [113].
The CSQ-8 is a self-report questionnaire consisting of 8
items characterised by high internal consistency (α = 0.93)
[111]. The adapted German version CSQ-I has been vali-
dated for the assessment of patient satisfaction with IMIs
and is characterised by equally high internal consistency
[113]. CSQ-I will be applied to assess satisfaction with
online-trainings in IG. An adapted version of the CSQ-I
will be applied in CG to evaluate satisfaction with infor-
mation material.Side effects of psychotherapy
Side effects of psychotherapy will be assessed with the
Inventory for the Assessment of Negative Effects of
Psychotherapy (INEP). The INEP records whether any
negative changes, which are experienced during or after
the treatment in the social and/or work environment, are
attributed on the psychotherapeutic intervention [114]. In
this trial, an adapted 22-item version covering possible
negative effects associated specifically with online-
trainings (e.g. concerns about data protection) is applied.
Additionally, an open question will be included for
qualitative assessments of negative side effects of IMIs.
Participants will describe experienced negative events and
side effects, their time of beginning, their frequency, and
their duration. Two further questions rate the negative
impact of these events in the past and at present time.
Other assessments
Medical condition
Participants will be requested to visit a general practi-
tioner and return a standardized formula for clarification
of medical condition. This procedure is applied to ensure
participants suffering from severe medical conditions re-
ceive appropriate medical care. Since the aim of the
present study is to evaluate effectiveness (not efficacy) of
online-trainings in standard care, the GP visit as well as
the return of the formula is left to the responsibility of the
participant. Further, the presence of diabetes mellitus will
be assessed using a self-report item as part of the psycho-
diagnostic assessment for the IMI program.
Covariates
As potential moderating variables, demographic informa-
tion (e.g. gender, age, education), information about the
agricultural farm (e.g. farm size, area cultivated, number
of workers), and about the situation of the entrepreneurial
family (e.g. financial situation, number of relatives living
and working together, general work load) will be recorded
at baseline. Further, a variety of predictors (e.g. personal-
ity, prior experience of violence and aggression, childhood
experiences) will be included to assess relevant factors for
development of depressive symptomology.
Procedure on suicidal ideations
Suicidal ideation will be screened using PHQ-9 in screening
assessment and QIDS-SR16 for further assessment points
(T0-T5). A score ≥ 1 on suicide item of PHQ-9 (“Thoughts
that you would be better off dead or of hurting yourself in
some way?”) or QIDS-SR16 (QIDS-SR16 Item= 1: “I feel
that life is empty or wonder if it’s worth living”, QIDS-SR16
Item= 2: “I think of suicide or death several times a week
for several minutes”, QIDS-SR16 Item= 3: “I think of sui-
cide or death several times a day in some detail, or I have
made specific plans for suicide or have actually tried to take
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BDI-II suicide item results in a standardized suicide proto-
col adapted from prior trials [115, 116].
Participants receive an online information letter with
detailed information on available health services and the
advice to seek professional help if symptoms increase. The
wording of the online information letter is adapted in em-
phasis, depending on the severity of the indicated suicidal-
ity (BDI-II Item = 1: “I have thoughts of killing myself, but
I would not carry them out”, BDI-II Item = 2: “I would like
to kill myself”, BDI-II-Item = 3: “I would kill myself if I
had the chance”). This procedure will be administered on
all assessment points and independent of study inclusion.
Eligible participants will be asked to return a signed
non-suicide contract as part of screening and baseline
(T0), if they are able to distance themselves from sui-
cidal ideation. Participants are informed that the IMI
program is not provided as intervention for problems ac-
companied by persisting suicidal ideation.
For BDI > 1, a detailed clarification of self-endangerment
will be performed for all screened participants inde-
pendent of study inclusion status and assessment
point. A telephone contact will be announced via e-
mail in case of not returning a given text module or
sending an informal answer in response to the online
information letter within 48 h of undergoing the as-
sessment point. If self-endangerment remains unclear,
psychotherapists (at least) in training will contact the
participant via telephone and initiate further actions.
Further actions will be determined depending on per-
ceived endangerment. If participant remains not con-
tactable for further 48 h, the police department will
be informed. All steps are closely monitored and su-
pervised by a licenced psychological psychotherapist.
Statistical analyses
Clinical analyses
All statistical analyses will be performed based on
intention-to-treat (ITT) principle. Patterns of missing data
will be examined and analyses will be corrected for miss-
ing data by applying multivariate imputation according to
Van Buuren and Groothuis-Oudshoorn [117]. For those
who substantially completed the intervention (at least 80%
of the modules) additional per-protocol (PP) analyses will
be conducted. Group difference between pre- and post-
assessment nine weeks after randomization (T1) in pri-
mary outcome will be assessed using generalized linear
modelling. Between-group effect size will be reported
using standardized mean differences and 95% CIs at all
measurement points. Reliable change index (RCI) and
number needed to treat (NNT) will be calculated to
determine clinical significance. Analysis of long-term ef-
fects will be adjusted to the data structure by using e.g. ro-
bust estimation of standard errors or mixed effectmodelling. Group differences in depression onset will be
assessed by calculation of a Poisson regression model. In-
cidence of clinical depression will be compared in IG and
CG by calculation of incidence rate ratio (IRR). Other sec-
ondary outcomes like perceived stress, sleep quality, and
quality of life will be analysed similarly as primary out-
come. Additionally, moderation and mediation analyses
will be performed.
Economic evaluation
The health-economic evaluation will involve a combin-
ation of a cost-effectiveness analysis (CEA) and a cost-
utility analysis (CUA). The economic evaluation will be
performed from a societal perspective (all relevant costs)
and a public health care perspective (only direct medical
costs) with a time horizon of 36months. In the cost-
effectiveness analysis, the incremental cost-effectiveness
ratio (ICER) will be based on the incremental costs per
unit of effect gained (e.g. reliably improved case based on
RCI). The corresponding equation is ICER = (CostsIG–
CostsCG)/(EffectsIG– EffectsCG), where Costs are the an-
nual per-participant costs and Effects are the unit of effect
in IG and CG. In the CUA, the ICER will be expressed as
incremental costs per quality adjusted life year (QALY)
gained as based on the AQoL-8D. Sampling uncertainty in
the ICER will be handled using nonparametric bootstrap-
ping by resampling on patient-level. In addition, confi-
dence intervals for ICERs will be obtained by
bootstrapped quantiles. The bootstrapped ICERs will be
plotted in a cost-effectiveness plane where the horizontal
axis reflects differences in effects and the vertical axis dif-
ferences in costs. The bootstrapped ICERs will also be
shown in a cost-effective acceptability curve disclosing the
probability that the intervention is cost-effective for a
range of willingness-to-pay ceilings. To test the robustness
of the base-case findings, multi-way sensitivity analyses
will be done. Several assumptions made in the base-case
scenario (e.g. about cost prices and volumes) will be chan-
ged to assess their impact on the ICERs.
Discussion
This study will be the first to investigate the clinical and
cost-effectiveness of a tailored, guided IMI program for
the prevention of depression and the reduction in de-
pressive symptom severity in green professions.
The proposed study is characterized by several strengths.
First, participants are provided with an IMI program with
the option of engaging in an IMI tailored to individual
needs. This might enlarge the reach of preventive IMIs by
avoiding the exclusive label of depression and associated
stigma. Further, this participatory and patient-centred ap-
proach might improve therapy motivation, if symptomatol-
ogy has a clinical burden and psychotherapy is indicated.
Also, the addressing of beliefs and needs of participants in
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might strengthen treatment credibility. Intrinsic motivation
and treatment credibility have been shown to positively re-
late to treatment adherence [34, 35]. Thereby, this
complaint-based approach might be able to improve the
overall impact of preventive internet-based interventions in
routine health care by a) increasing the uptake of a prevent-
ive IMI program and b) by improving adherence to the IMI
program. A large-scale dissemination is especially in pre-
vention context highly desirable to reduce overall depres-
sion burden in population as well as associated health care
costs. If proven effective, further studies could evaluate the
proposed IMI program regarding its reach compared to
single IMIs build, labelled and advertised solely as a depres-
sion prevention intervention. Second, we will be able to in-
vestigate long-term effectiveness of the IMI program.
Previous research yielded few and inconsistent results re-
garding long-term efficacy of psychological interventions
for subthreshold depression [18] and IMIs in particular
[26]. This study will not only evaluate positive treatment ef-
fects, but also possible side effects of the IMI program.
Since side effects of preventive IMIs in both short and long
terms have not been sufficiently explored yet, this study will
be able to provide a detailed understanding about positive
and negative treatment effects of the proposed IMI pro-
gram. Third, we will be able to conduct long-term cost-
effectiveness analyses over a 36-month period. Evaluation
of a guided IMI for depression prevention has already been
shown to yield acceptable cost-effectiveness in preventing
onset of clinical depression in people with subthreshold de-
pression over a 12-month evaluation period [56]. However,
cost-effectiveness might be less pronounced over a longer
follow-up period [56] since results of a first meta-analytic
review indicate that effectiveness of psychological interven-
tions for prevention of depression might decline with lon-
ger follow-up periods [19]. The present study aims to yield
first results regarding cost-effectiveness of an IMI program
for prevention of depression over an extensive follow-up
period of 36months to close this knowledge gap. Forth, as
a unique feature of the present trial, (cost)effectiveness of
an IMI program provided in routine health care provided
by the service provider GET.ON will be examined. Based
on the pragmatic setting, this effectiveness trial is character-
ized by high external validity and generalizability regarding
the target group of green professions [118, 119]. The effi-
cacy of the employed IMIs in reduction of depressive symp-
tomology has already been demonstrated in previous
studies [23–25, 48–55]. For the present trial, the IMI pro-
gram has been adapted to the context of green professions
by the service provider to evaluate effectiveness in routine
health care of the target group. Effectiveness and cost-
effectiveness is especially interesting against the background
of ongoing implementation of this IMI program into stand-
ard health care. Thereby, the present trial evaluates clinicaland cost-effectiveness of a prospective supply situation in
German preventive health care.
Limitations of the present study encompass that, firstly,
intervention and study dropout must be considered
against the background of such an extensive follow-up
period to generate reliable results regarding long-term
(cost)effectiveness of the proposed IMI program. Espe-
cially participants of the CG are expected to be at risk for
study dropout, since they do not get access to the IMI
program during the follow-up period of 36months. To
improve study adherence, incentives for completion of
online-assessments and standardized reminding proce-
dures are applied. To reduce intervention dropout, IMIs
have been adapted in content for green professions and
therapeutic guidance is deployed. Dropout can be reduced
by providing therapeutic guidance [69]. Additionally, the
high number of measurement points could lead to repeti-
tion effects like automatic response tendencies, which
might limit the informative value of the measurement.
Second, representativeness of the investigated sample and
generalizability to the target population of green profes-
sions might be limited to some degree because of two as-
pects; for one, high comorbidity between chronic pain and
depressive disorders [120] might lead to a substantial pro-
portion of participants choosing participation in the re-
lated trial addressing chronic pain (PACT-A, (Terhorst Y,
Braun L, Titzler I, Buntrock C, Freund J, Thielecke J, et
al.: Effectiveness and cost-effectiveness of an acceptance
and commitment therapy to improve chronic pain-related
disability in green professions (PACT-A): study protocol
of a 36-month follow up pragmatic randomized controlled
trial, in preparation)) instead of the present trial, possibly
resulting in an underrepresentation of participants with
chronic pain in the present study sample. On the other
hand, internet access as well as access to an appropriate
device (e.g. computer, tablet, smartphone) and basic
knowledge of its functioning are an elementary prerequis-
ite for participation in the present trial and the usage of
the IMI program. Both might be limited, especially in
rural areas, which might systematically lead to the exclu-
sion of persons who have either insufficient internet con-
nection nor the means or the knowledge to work with the
required electronic devices. Thus, the present trial will
only be representative for the population with the possibil-
ity to access the intervention at hand. This limitation is
not specific to IMIs but a general limitation of RCTs that
are always only representative to the populations who can
access the intervention (e.g. on site-interventions only for
those who are sufficiently mobile). Third, presence of clin-
ical depression will not be assessed with standardized
diagnostic procedures at baseline or follow-up. Since
QIDS-SR16 has been shown to have high predictive valid-
ity as a screening instrument for MDD [77], this instru-
ment was applied to identify possible cases of MDD.
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was defined as eligibility criteria. Therefore, possible cases
of manifest clinical depression might be included in the
present trial. The present study reflects service reality in
this that people with manifest mental disorders can make
use of preventive interventions in the absence of struc-
tured diagnostic procedures. We will perform categorical
analyses of acquired data to estimate percentage of pos-
sible cases of illness included. This might provide first in-
sights into actual utilization and impact of preventive
interventions in routine health care regarding (lacking)
differentiation between subthreshold and manifest clinical
depression.
Internet-based preventive interventions have the poten-
tial to improve the general care situation substantially,
specifically in rural areas, provided that the proposed
health care offer encounters reasonable acceptance and
utilization in green professions. The proposed tailored
prevention approach is thought to improve dissemination
of preventive interventions aiming to overcome depressive
symptoms or risk factors for development of depression.
Such prevention approaches can contribute to reduction
of chronification and overall depression burden in green
professions. This in turn can result in decrease of sick
days, incapacity to work and early retirement, and thus a
substantial cost reduction in the health care sector of
green professions. If proven effective, implementation of
the proposed IMI program into routine health care of
green professions will have a large public health impact.
Trial status
The study is currently ongoing. Recruitment started in
January 2018 and was concluded in April 2019.
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